Adding checkpoint inhibition to anti-HER2 breast cancer therapy brings no benefit
Researchers develop new imaging agent to detect activated platelets
17 June 2021Incidents of serious parasitic disease on the rise in Alberta, Canada
18 June 2021Adding checkpoint inhibition to anti-HER2 breast cancer therapy brings no benefit
Adding an immune checkpoint inhibitor to anti-HER2 treatment in breast cancer does not improve pathological complete response (pCR), according to the primary analysis of the IMpassion050 trial presented today during the ESMO Virtual Plenary. The phase III trial is the first to report data comparing a neoadjuvant anti-HER2 based regimen with or without the anti-PD-L1 antibody atezolizumab in patients with high-risk, HER2-positive early breast cancer.
